DRC & Research News

This page shares the latest news in T1D research and DRC’s community.

Get the most recent diabetes research news, delivered straight to your inbox

Diabetes Research

DRC’s investment in T1D cures continues! RFA 2023 is now open!

Diabetes Research Connection’s next round of type 1 diabetes (T1D) research funding has begun.  We are excited to announce that our 2023 Request for Application (RFA) period is NOW OPEN! 

We sent out notifications to hundreds of research institutes and T1D scientists around the country, encouraging all early-career investigators to submit their proposals for research grant funding.

Our investment in research is focused on innovation, and we are funding more research than ever – encouraging fresh ideas and providing the means for a new generation of diabetes investigators to go where no one else is going to solve the complex diabetes puzzle. If they have an innovative idea – we will help get it funded!

Last year alone, DRC committed to funding eleven new projects from all across the country.

We will not stop until diabetes is eliminated, and your generous contributions allow us to continue progressing forward in that goal.

If you would like to support our next group of brilliant minds committed to T1D cures, please make a gift today. Click DONATE NOW on the top right of this page.

If you are a researcher and would like to submit your proposal, click HERE.

Learn More +
Pills metformin

Potential Benefits of Incorporating C4H11N5 in Type 1 Diabetes Treatment

Metformin: A Potential Game-Changer in Type 1 Diabetes Management

The journey of managing diabetes is a complex one, impacted by a myriad of factors affecting blood sugar levels. One such factor is the type of medication utilized. For people living with type 2 diabetes, Metformin is a well-known medication, typically employed to regulate blood sugar levels. Recently, however, it has emerged into the spotlight for a different reason – its potential benefits in treating type 1 diabetes. This surprising finding can be traced back to a recent study examining Metformin’s impact on vascular health, presenting a new ray of hope for healthcare professionals and individuals diagnosed with type 1 diabetes. This novel application is especially noteworthy, as those living with type 1 diabetes frequently face an elevated risk of cardiovascular disease – a life-threatening condition if left unchecked.

The Groundbreaking Study

Researchers undertook a meticulously conducted double-blind, randomized, placebo-controlled trial. The participants were 90 children aged 8 to 18, all hailing from South Australia, and each one had been navigating life with type 1 diabetes for at least six months. These participants were split into two equally sized groups. One group received Metformin, while the other was given a placebo.

In addition to administering the trial’s medication, the researchers paid close attention to a few crucial parameters that are known to affect blood sugar levels. HbA1C, which provides an overview of blood sugar control over the past 2-3 months, insulin dose, and BMI were meticulously recorded. The team also incorporated the use of a continuous glucose monitoring (CGM) system, an advanced technology providing real-time glucose readings, an invaluable tool in achieving a granular level of insight into blood sugar control.

Dietary Factors and Blood Sugar Control

Throughout the trial, the participants’ diet was carefully observed, focusing on foods that vary in their glycemic index (GI), a measure that ranks carbohydrate-containing foods by how much they boost blood sugar levels. Foods with a high GI, including white rice and white bread, have a significant impact on blood glucose levels, causing spikes that can be detrimental if not managed effectively.

The importance of maintaining a balance in blood sugar levels was also emphasized throughout the trial. The target range for each participant was meticulously defined, aiming to keep it above 70mg/dl to prevent hypoglycemia (low blood sugar), and below a specified threshold to avoid hyperglycemia (high blood sugar). Frequent blood glucose monitoring played a critical role in maintaining this equilibrium, with the participants encouraged to use their blood glucose meter consistently.

Results and Potential Implications

The trial produced promising results. Over the year, the Metformin group showed distinct improvement in vascular function over the placebo group. This was most noticeable at the three-month interval. Interestingly, this was also when a significant decrease in HbA1C levels was recorded, indicating better control of blood sugar. By the 12-month mark, although the difference was lower, it remained significant. Furthermore, the Metformin group required less insulin, suggesting a decrease in insulin resistance – an encouraging development.

Another noteworthy finding was that children with above-average BMIs who were taking Metformin showed a marked improvement in vascular smooth muscle function. This improvement is indicative of better overall vascular health, which, in turn, can help reduce the risk of cardiovascular disease – a common complication for those living with type 1 diabetes.

While these findings offer hope for more diverse treatment options for people with type 1 diabetes, it’s important to note that the study didn’t run long enough to determine potential changes in vascular structure, only vascular function. Nevertheless, the potential implications are exciting.

Conclusion: Hope for the Future

If Metformin can indeed help in better managing type 1 diabetes, this could herald a new era in diabetes care. Improved diabetes management could lead to a higher quality of life for individuals living with the condition. With more research, the question of how to control blood sugar could become easier to answer, particularly if Metformin proves to be an effective part of the solution.

As we move forward, this type of groundbreaking study underlines the critical importance of continued research in the field of diabetes. At Diabetes Research Connection, we are committed to supporting advancements like this by funding novel research projects. We believe in the power of scientific discovery to transform lives and improve the future for those living with diabetes. We invite you to join us on this journey and support this life-changing mission. Visit https://diabetesresearchconnection.org to learn more about our initiatives and see how you can make a difference. Together, we can chart a brighter path toward managing, and ultimately curing, diabetes.

Learn More +

OUR PROJECTS

See our approved research projects and campaigns.

Role of the integrated stress response in type 1 diabetes pathogenesis
In individuals with type 1 diabetes (T1D), the insulin-producing beta cells are spontaneously destroyed by their own immune system. The trigger that provokes the immune system to destroy the beta cells is unknown. However, accumulating evidence suggest that signals are perhaps first sent out by the stressed beta cells that eventually attracts the immune cells. Stressed cells adapt different stress mitigation systems as an adaptive response. However, when these adaptive responses go awry, it results in cell death. One of the stress response mechanisms, namely the integrated stress response (ISR) is activated under a variety of stressful stimuli to promote cell survival. However, when ISR is chronically activated, it can be damaging to the cells and can lead to cell death. The role of the ISR in the context of T1D is unknown. Therefore, in this DRC funded study, we propose to study the ISR in the beta cells to determine its role in propagating T1D.
Wearable Skin Fluorescence Imaging Patch for the Detection of Blood Glucose Level on an Engineered Skin Platform
zhang
A Potential Second Cure for T1D by Re-Educating the Patient’s Immune System
L Ferreira
Validating the Hypothesis to Cure T1D by Eliminating the Rejection of Cells From Another Person by Farming Beta Cells From a Patient’s Own Stem Cells
Han Zhu
Taming a Particularly Lethal Category of Cells May Reduce/Eliminate the Onset of T1D
JRDwyer 2022 Lab 1
Can the Inhibition of One Specific Body Gene Prevent Type 1 Diabetes?
Melanie
Is Cholesterol Exacerbating T1D by Reducing the Functionality and Regeneration Ability of Residual Beta Cells?
Regeneration Ability of Residual Beta Cells
A Call to Question… Is T1D Caused by Dysfunctionality of Two Pancreatic Cells (β and α)?
Xin Tong
Novel therapy initiative with potential path to preventing T1D by targeting TWO components of T1D development (autoimmune response and beta-cell survival)
flavia pecanha